

THE COOPER COMPANIES, INC.
Presentation of Historical Saufon Pharmaceuticals Ltd. Financial Information
(USD, in Thousands, Non-GAAP, Unaudited)

The Cooper Companies, Inc. Historical Financial Information (Non-GAAP, Unaudited)									
	FY 2013					FY 2014			
	Q1	Q2	Q3	Q4	Total	Q1	Q2	Q3	Nine months ended July 31
Net sales	\$ 379,839	\$ 384,041	\$ 411,993	\$ 411,852	\$ 1,587,725	\$ 404,980	\$ 412,317	\$ 432,482	\$ 1,249,779
Cost of sales	139,341	129,862	143,719	147,994	560,916	142,051	143,818	151,465	437,334
Gross profit	240,498	254,179	268,274	263,858	1,026,809	262,929	268,499	281,017	812,445
GM%	63.3%	66.2%	65.1%	64.1%	64.7%	64.9%	65.1%	65.0%	65.0%
Selling, general and administrative	150,027	150,693	152,142	157,247	610,109	158,088	154,818	156,492	469,398
Research and development	13,654	14,489	14,865	15,819	58,827	15,712	16,295	16,070	48,077
Operating income	76,817	88,997	101,267	90,792	357,873	89,129	97,386	108,455	294,970
OI%	20.2%	23.2%	24.6%	22.0%	22.5%	22.0%	23.6%	25.1%	23.6%
Interest expense	2,567	2,443	2,258	1,900	9,168	1,656	1,558	1,499	4,713
Other expense (income), net	(637)	89	86	(949)	(1,411)	511	(455)	683	739
Income before income taxes	74,887	86,465	98,923	89,841	350,122	86,962	96,283	106,273	289,518
Provision for income taxes	7,920	6,105	6,356	10,283	30,664	8,895	9,961	7,741	26,597
Net income	66,967	80,360	92,567	79,558	319,458	78,067	86,322	98,532	262,921
Less: income (loss) attributable to noncontrolling interests	336	399	341	2	1,078	491	544	675	1,710
Net income attributable to Cooper stockholders	\$ 66,631	\$ 79,961	\$ 92,226	\$ 79,556	\$ 318,374	\$ 77,576	\$ 85,778	\$ 97,857	\$ 261,211
Earnings per share attributable to Cooper stockholders - diluted	1.34	1.62	1.85	1.60	6.41	1.58	1.76	2.00	5.34
Number of shares used to compute earnings per share - diluted	49,633	49,478	49,754	49,723	49,685	49,006	48,754	48,922	48,901

Saufon Pharmaceuticals Ltd. Historical Financial Information (Non-GAAP, Unaudited)									
	FY 2013					FY 2014			
	Q1	Q2	Q3	Q4	Total	Q1	Q2	Q3	Nine months ended July 31
Net sales	\$ 34,506	\$ 38,144	\$ 44,522	\$ 41,427	\$ 158,599	\$ 43,809	\$ 47,359	\$ 49,269	\$ 140,437
Cost of sales	17,839	18,608	20,992	19,733	77,172	22,146	23,377	24,050	69,573
Gross profit	16,667	19,536	23,530	21,694	81,427	21,663	23,982	25,219	70,864
GM%	48.3%	51.2%	52.9%	52.4%	51.3%	49.4%	50.6%	51.2%	50.5%
Selling, general and administrative	11,725	13,638	14,569	14,525	54,457	16,302	18,796	21,229	56,327
Research and development	441	423	428	780	2,072	674	707	691	2,072
Operating income	4,501	5,475	8,533	6,389	24,898	4,687	4,479	3,299	12,465
OI%	13.0%	14.4%	19.2%	15.4%	15.7%	10.7%	9.5%	6.7%	8.9%
Interest expense	799	799	799	3,143	5,540	1,509	1,509	1,509	4,527
Other expense (income), net	-	-	(2)	(779)	(781)	(959)	(959)	(959)	(2,877)
Income before income taxes	3,702	4,676	7,736	4,025	20,139	4,137	3,929	2,749	10,815
Provision for income taxes	556	1,241	1,925	(1,071)	2,651	1,236	1,302	1,478	4,016
Net income	\$ 3,146	\$ 3,435	\$ 5,811	\$ 5,096	\$ 17,488	\$ 2,901	\$ 2,627	\$ 1,271	\$ 6,799

The Cooper Companies, Inc. and Saufon Pharmaceuticals Ltd. Combined Historical Financial Information (Non-GAAP, Unaudited)									
	FY 2013					FY 2014			
	Q1	Q2	Q3	Q4	Total	Q1	Q2	Q3	Nine months ended July 31
Net sales	\$ 414,345	\$ 422,185	\$ 456,515	\$ 453,279	\$ 1,746,324	\$ 448,789	\$ 459,676	\$ 481,751	\$ 1,390,216
Cost of sales	157,180	148,470	164,711	167,727	638,088	164,197	167,195	175,515	506,907
Gross profit	257,165	273,715	291,804	285,552	1,108,236	284,592	292,481	306,236	883,309
GM%	62.1%	64.8%	63.9%	63.0%	63.5%	63.4%	63.6%	63.6%	63.5%
Selling, general and administrative	161,752	164,331	166,711	171,772	664,566	174,390	173,614	177,721	525,725
Research and development	14,095	14,912	15,293	16,599	60,899	16,386	17,002	16,761	50,149
Operating income	81,318	94,472	109,800	97,181	382,771	93,816	101,865	111,754	307,435
OI%	19.6%	22.4%	24.1%	21.4%	21.9%	20.9%	22.2%	23.2%	22.1%
Interest expense	3,366	3,242	3,057	5,043	14,708	3,165	3,067	3,008	9,240
Other expense (income), net	(637)	89	84	(1,728)	(2,192)	(448)	(1,414)	(276)	(2,138)
Income before income taxes	78,589	91,141	106,659	93,866	370,255	91,099	100,212	109,022	300,333
Provision for income taxes	8,476	7,346	8,281	9,212	33,315	10,131	11,263	9,219	30,613
Net income	70,113	83,795	98,378	84,654	336,940	80,968	88,949	99,803	269,720
Less: income (loss) attributable to noncontrolling interests	336	399	341	2	1,078	491	544	675	1,710
Net income attributable to Cooper stockholders	\$ 69,777	\$ 83,396	\$ 98,037	\$ 84,652	\$ 335,862	\$ 80,477	\$ 88,405	\$ 99,128	\$ 268,010
Earnings per share attributable to Cooper stockholders - diluted	1.40	1.69	1.97	1.70	6.76	1.64	1.81	2.03	5.48
Number of shares used to compute earnings per share - diluted	49,633	49,478	49,754	49,723	49,685	49,006	48,754	48,922	48,901

The Cooper Companies, Inc. and CooperVision Non-GAAP financial results exclude amortization and other costs as described in our Earnings Releases for the period referenced.

These may be accessed on the Investor Relations page of our website www.cooperco.com.

Saufon Pharmaceuticals Ltd. Non-GAAP financial results exclude amortization.

THE COOPER COMPANIES, INC.
Presentation of Historical Sauflon Pharmaceuticals Ltd. Financial Information
(USD, in Thousands, Non-GAAP, Unaudited)

CooperVision, Inc. Historical Financial Information (Non-GAAP, Unaudited)

	FY 2013					FY 2014			
	Q1	Q2	Q3	Q4	Total	Q1	Q2	Q3	Nine months ended July 31
Net sales	\$ 301,379	\$ 309,348	\$ 330,520	\$ 327,072	\$ 1,268,319	\$ 326,303	\$ 331,082	\$ 349,900	\$ 1,007,285
Cost of sales	111,143	103,364	114,433	117,739	446,679	113,044	115,146	123,201	351,391
Gross profit	190,236	205,984	216,087	209,333	821,640	213,259	215,936	226,699	655,894
GM%	63.1%	66.6%	65.4%	64.0%	64.8%	65.4%	65.2%	64.8%	65.1%
Selling, general and administrative	108,627	111,041	111,987	116,567	448,222	112,012	116,357	117,242	345,611
Research and development	10,466	11,435	11,912	12,560	46,373	12,835	12,581	12,478	37,894
Operating income	\$ 71,143	\$ 83,508	\$ 92,188	\$ 80,206	\$ 327,045	\$ 88,412	\$ 86,998	\$ 96,979	\$ 272,389
OI%	23.6%	27.0%	27.9%	24.5%	25.8%	27.1%	26.3%	27.7%	27.0%

Sauflon Pharmaceuticals Ltd. Historical Financial Information (Non-GAAP, Unaudited)

	FY 2013					FY 2014			
	Q1	Q2	Q3	Q4	Total	Q1	Q2	Q3	Nine months ended July 31
Net sales	\$ 34,506	\$ 38,144	\$ 44,522	\$ 41,427	\$ 158,599	\$ 43,809	\$ 47,359	\$ 49,269	\$ 140,437
Cost of sales	17,839	18,608	20,992	19,733	77,172	22,146	23,377	24,050	69,573
Gross profit	16,667	19,536	23,530	21,694	81,427	21,663	23,982	25,219	70,864
GM%	48.3%	51.2%	52.9%	52.4%	51.3%	49.4%	50.6%	51.2%	50.5%
Selling, general and administrative	11,725	13,638	14,569	14,525	54,457	16,302	18,796	21,229	56,327
Research and development	441	423	428	780	2,072	674	707	691	2,072
Operating income	\$ 4,501	\$ 5,475	\$ 8,533	\$ 6,389	\$ 24,898	\$ 4,687	\$ 4,479	\$ 3,299	\$ 12,465
OI%	13.0%	14.4%	19.2%	15.4%	15.7%	10.7%	9.5%	6.7%	8.9%

CooperVision, Inc. and Sauflon Pharmaceuticals Ltd. Combined Historical Financial Information (Non-GAAP, Unaudited)

	FY 2013					FY 2014			
	Q1	Q2	Q3	Q4	Total	Q1	Q2	Q3	Nine months ended July 31
Net sales	\$ 335,885	\$ 347,492	\$ 375,042	\$ 368,499	\$ 1,426,918	\$ 370,112	\$ 378,441	\$ 399,169	\$ 1,147,722
Cost of sales	128,982	121,972	135,425	137,472	523,851	135,190	138,523	147,251	420,964
Gross profit	206,903	225,520	239,617	231,027	903,067	234,922	239,918	251,918	726,758
GM%	61.6%	64.9%	63.9%	62.7%	63.3%	63.5%	63.4%	63.1%	63.3%
Selling, general and administrative	120,352	124,679	126,556	131,092	502,679	128,314	135,153	138,471	401,938
Research and development	10,907	11,858	12,340	13,340	48,445	13,509	13,288	13,169	39,966
Operating income	\$ 75,644	\$ 88,983	\$ 100,721	\$ 86,595	\$ 351,943	\$ 93,099	\$ 91,477	\$ 100,278	\$ 284,854
OI%	22.5%	25.6%	26.9%	23.5%	24.7%	25.2%	24.2%	25.1%	24.8%

The Cooper Companies, Inc. and CooperVision Non-GAAP financial results exclude amortization and other costs as described in our Earnings Releases for the period referenced.

These may be accessed on the Investor Relations page of our website www.coopercos.com.

Sauflon Pharmaceuticals Ltd. Non-GAAP financial results exclude amortization.